<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429143</url>
  </required_header>
  <id_info>
    <org_study_id>06U.20</org_study_id>
    <secondary_id>2005-84</secondary_id>
    <nct_id>NCT00429143</nct_id>
  </id_info>
  <brief_title>A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative</brief_title>
  <official_title>A Two Step Approach To Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies From HLA Partially-Matched Related Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a way of treating patients who do not have a
      completely matched family donor or a readily available unrelated donor with bone marrow
      transplant by using a partially-matched family donor. Patients receiving this type of
      transplant will receive chemotherapy and/or radiation to treat their disease. They will also
      receive their donor's cells in 2 parts. During the first part, the donor's lymphocytes will
      be exposed to one of the chemotherapy agents to help the patient become tolerant to the
      lymphocytes. In the second part of the transplant, the patient will receive their donor's
      stem cells to help recover their peripheral blood counts and establish long-term engraftment.
      The hypothesis of this study is that in partially-matched allogeneic transplant, there is a
      defined number of donor T-cells that can be treated and given to the recipient to avoid
      post-transplant infection without causing severe graft-versus-host disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haploidentical hematopoietic stem cell transplant is a life-saving therapy for patients who
      are without well matched donors. This type of therapy has been associated with poor outcomes
      in the past due to complications such as infection. The Jefferson 2 Step approach was
      designed to allow the infusion of an exact dose of tolerized lymphocytes in haploidentical
      transplant in order to allow for immune reconstitution post transplant to avoid infectious
      complications while still having acceptable rates of GVHD. In this approach, patients with
      high-risk hematological malignancies undergo 8 fractions of TBI (12 Gy) followed by an exact
      dose of donor lymphocytes. The phase I portion of the study determined the optimal dose of
      lymphocytes. Two days after receiving the donor lymphocytes, the patients receive 2 daily
      doses of cyclophosphamide. One day after receiving cyclophosphamide, the patients receive
      stem cell from their donor. Tacrolimus and mycophenylate mofetil are used as GVHD
      prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival of Participants</measure>
    <time_frame>6 months</time_frame>
    <description>To determine overall survival at 6 months post-transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal Dose of CD3+ Donor Lymphocytes (T-cells) for Consistent Engraftment Without GVHD</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the optimal dose of CD3+ donor lymphocytes required for consistent engraftment without the development of grade III/IV GVHD.
Measured as CD3+ donor lymphocytes given as n x 10^8/kg.
&quot;n&quot; was found to be 2 and was found to be the optimal dose and was the only dose given.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment Rates</measure>
    <time_frame>6 months</time_frame>
    <description>To assess hematopoietic engraftment rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoid Recovery</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the pace of lymphoid recovery in this patient population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grades III-IV GVHD</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the incidence and severity of GVHD in these patients using a combination of cyclophosphamide, tacrolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis.'
Severity was graded using CTCAE 3.0 (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>TBI twice daily days 6-9 prior to transplant (HSCT)</description>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor Lymphocyte Infusion (DLI)</intervention_name>
    <description>DLI given 6 days prior to transplant (HSCT).</description>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <other_name>DLI</other_name>
    <other_name>T cell infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CY)</intervention_name>
    <description>Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).</description>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <other_name>CY</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus given one day prior to transplant (HSCT).</description>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil (MMF)</intervention_name>
    <description>MMF given one day prior to transplant (HSCT).</description>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplant (HSCT)</intervention_name>
    <description>CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.</description>
    <arm_group_label>Haploidentical Allogeneic Transplantation</arm_group_label>
    <other_name>HSCT</other_name>
    <other_name>stem cell transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is
             thought to be beneficial, and in whom front-line therapy has already been applied.

          2. Patients must have a related donor who is either a one, two or three out of six
             antigen mismatch at the HLA-A;B;DR loci.

          3. Patients without a well-matched unrelated donor or those who have a disease status
             that precludes a wait for an identified unrelated donor.

          4. Patients must adequate organ function:

               -  LVEF of &gt;45%

               -  FVC or FEV1 &gt;45% of predicted

               -  Adequate liver function as defined by a serum bilirubin &lt;1.8, AST or ALT &lt; 2.5X
                  upper limit of normal

               -  Serum creatinine &lt; 2.0 mg/dl or creatinine clearance of &gt; 40 ml/min

          5. Performance status &gt; 60% (Karnofsky)

          6. Patients must be willing to use contraception if they have childbearing potential

          7. Able to give informed consent

        Exclusion Criteria:

          1. An eligible HLA-identical sibling donor.

          2. Performance status &lt; 60% (Karnosfsky)

          3. HIV positive

          4. Active involvement of the central nervous system with malignancy

          5. Psychiatric disorder that would preclude patients from signing an informed consent

          6. Pregnancy

          7. Patients with life expectancy of &lt; 6 months for reasons other than their underlying
             hematologic/oncologic disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>June 4, 2012</results_first_submitted>
  <results_first_submitted_qc>May 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 31, 2013</results_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Two Step Approach</keyword>
  <keyword>Haploidentical Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients presenting to Thomas Jefferson University with hematological malignancies requiring hematopoeitic stem cell transplantation without matched related donors. Opened January, 2006 through August, 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Haploidentical Allogeneic Transplantation</title>
          <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haploidentical Allogeneic Transplantation</title>
          <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival of Participants</title>
        <description>To determine overall survival at 6 months post-transplant.</description>
        <time_frame>6 months</time_frame>
        <population>27 Patients undergoing haploidentical transplant at Thomas Jefferson University</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplantation</title>
            <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival of Participants</title>
          <description>To determine overall survival at 6 months post-transplant.</description>
          <population>27 Patients undergoing haploidentical transplant at Thomas Jefferson University</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Optimal Dose of CD3+ Donor Lymphocytes (T-cells) for Consistent Engraftment Without GVHD</title>
        <description>To determine the optimal dose of CD3+ donor lymphocytes required for consistent engraftment without the development of grade III/IV GVHD.
Measured as CD3+ donor lymphocytes given as n x 10^8/kg.
&quot;n&quot; was found to be 2 and was found to be the optimal dose and was the only dose given.</description>
        <time_frame>6 months</time_frame>
        <population>Two patients died prior to expected day of engraftment</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplantation</title>
            <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Dose of CD3+ Donor Lymphocytes (T-cells) for Consistent Engraftment Without GVHD</title>
          <description>To determine the optimal dose of CD3+ donor lymphocytes required for consistent engraftment without the development of grade III/IV GVHD.
Measured as CD3+ donor lymphocytes given as n x 10^8/kg.
&quot;n&quot; was found to be 2 and was found to be the optimal dose and was the only dose given.</description>
          <population>Two patients died prior to expected day of engraftment</population>
          <units>lymphocytes x 10^8/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Engraftment Rates</title>
        <description>To assess hematopoietic engraftment rates.</description>
        <time_frame>6 months</time_frame>
        <population>Two patients died prior to expected engraftment day</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplantation</title>
            <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Rates</title>
          <description>To assess hematopoietic engraftment rates.</description>
          <population>Two patients died prior to expected engraftment day</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphoid Recovery</title>
        <description>To assess the pace of lymphoid recovery in this patient population.</description>
        <time_frame>6 months</time_frame>
        <population>Two patients did not engraft, two patients died prior to expected day of engraftment</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplantation</title>
            <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphoid Recovery</title>
          <description>To assess the pace of lymphoid recovery in this patient population.</description>
          <population>Two patients did not engraft, two patients died prior to expected day of engraftment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grades III-IV GVHD</title>
        <description>To determine the incidence and severity of GVHD in these patients using a combination of cyclophosphamide, tacrolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis.'
Severity was graded using CTCAE 3.0 (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death)</description>
        <time_frame>6 months</time_frame>
        <population>Two patients died prior to expected engraftment. Two patients who rejected were retransplanted and were evaluable for GVHD.</population>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplantation</title>
            <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grades III-IV GVHD</title>
          <description>To determine the incidence and severity of GVHD in these patients using a combination of cyclophosphamide, tacrolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis.'
Severity was graded using CTCAE 3.0 (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death)</description>
          <population>Two patients died prior to expected engraftment. Two patients who rejected were retransplanted and were evaluable for GVHD.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Haploidentical Allogeneic Transplantation</title>
          <description>Patients undergoing hematopoietic stem cell transplant from a partially matched related donor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death - Disease progression NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Death - Multi-organ failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms – Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Death - Death NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <description>Hepatic failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome/acute infusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Opportunistic infection associated with &gt;=Grade 2 Lymphopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary – Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary – Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of the trial include small sample size and single institution</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Neal Flomenberg, MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215-955-4367</phone>
      <email>neal.flomenberg@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

